Cargando…

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort

OBJECTIVE: To assess disease activity within 12 months after natalizumab (NZ) discontinuation in a large French postmarketing cohort. METHODS: In France, patients exposed at least once to NZ were included in the TYSEDMUS observational and multicenter cohort, part of the French NZ Risk Management Pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papeix, Caroline, Vukusic, Sandra, Casey, Romain, Debard, Nadine, Stankoff, Bruno, Mrejen, Serge, Uhry, Zoe, Van Ganse, Eric, Castot, Anne, Clanet, Michel, Lubetzki, Catherine, Confavreux, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087255/ https://www.ncbi.nlm.nih.gov/pubmed/27844037 http://dx.doi.org/10.1212/NXI.0000000000000297

Ejemplares similares

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

COVID-19 infection in NMO/SD patients: a French survey
por: Zeidan, Sinéad, et al.
Publicado: (2020)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
por: Roux, Thomas, et al.
Publicado: (2017)

Perceptions of French general practitioners and patients regarding dextropropoxyphene withdrawal: a qualitative study
por: Combier, Aurélie, et al.
Publicado: (2018)

Demyelination in multiple sclerosis
por: Lubetzki, Catherine, et al.
Publicado: (2014)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
por: Leray, Emmanuelle, et al.
Publicado: (2015)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
por: Pelle, Juliette, et al.
Publicado: (2023)

FRENCH versus ESI: comparison between two nurse triage emergency scales with referent scenarios
por: Aubrion, Antoine, et al.
Publicado: (2022)

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France
por: Pivot, Diane, et al.
Publicado: (2016)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Comparison between two triage scales requires testing users who do not have a known scale, with referent scenarios including all pathologies: Response letter to Miraghi about our study: FRENCH versus ESI: comparison between two nurse triage emergency scales with referent scenarios published in BMC Emergency Medicine: doi.org/10.1186/s12873-022-00752-z
por: Aubrion, Antoine, et al.
Publicado: (2023)

Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis
por: Bayen, E., et al.
Publicado: (2015)

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Use of analgesics in France, following dextropropoxyphene withdrawal
por: Van Ganse, E., et al.
Publicado: (2018)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
por: Dubois-Dalcq, Monique, et al.
Publicado: (2008)

Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
por: Louapre, C., et al.
Publicado: (2020)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis
por: Bodini, Benedetta, et al.
Publicado: (2016)

Withholding and withdrawing life support: national French prospective study
por: Ferrand, E, et al.
Publicado: (1999)

Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
por: Mouzaki, Athanasia, et al.
Publicado: (2010)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f4k5do78cdhc9a52rrpvkus59m